当前位置: 首页 > 详情页

Safety of catheter ablation for atrial fibrillation in patients with intracranial hemorrhage

Safety of catheter ablation for atrial fibrillation in patients with intracranial hemorrhage

文献详情

资源类型:

收录情况: ◇ SCIE

机构: [1]Department of Cardiology, Beijing Anzhen Hospital, CapitalMedical University, Beijing, China
出处:
ISSN:

关键词: Anticoagulation agents Atrial fibrillation Heparin Intracranial hemorrhages Radiofrequency catheter ablation

摘要:
Background: The safety of anticoagulation and radiofrequency catheter ablation (RFCA) in patients with atrial fibrillation (AF) and a history of intracranial hemorrhage (ICH) remains unclear. We investigated the risks and benefits of this approach in AF patients with a history of ICH. Patients and methods: The ICH group included 45 AF patients with a history of ICH who underwent RFCA. Five of these patients were excluded because ICH occurred spontaneously after cerebral infarction. The control group included 80 individuals who presented for AF ablation and did not have a history of ICH. Two controls were matched for each study group patient in terms of sex, age (±2 years), type of AF, and procedure date. Results: Patients in the ICH group had higher CHADS2 (1.7 ± 1.3 vs. 1.1 ± 1.2, p OpenSPiltSPi 0.05), CHA2DS2-VASc (2.6 ± 1.7 vs. 1.9 ± 1.6, p OpenSPiltSPi 0.05), and HAS-BLED scores (2.5 ± 1.0 vs. 1.1 ± 1.0, p OpenSPiltSPi 0.001). All participants in both groups underwent successful RFCA. The incidence of ICH during follow-up (1 vs. 0, p = 0.333) was similar between the ICH and control groups. AF-free survival between the two groups was not significant (log-rank p = 0.283) within the first 3 months, but was significant (log-rank p = 0.011) within 48 months of RFCA. History of ICH was the only independent predictor of AF recurrence according to univariate Cox regression analysis. Conclusion: In AF patients with a history of ICH, AF ablation with a standard anticoagulation strategy is safe and does not seem to be associated with an increased risk of hemorrhage. © 2017, Springer Medizin Verlag GmbH.

基金:
语种:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2017]版:
大类 | 4 区 医学
小类 | 4 区 心脏和心血管系统
最新[2023]版:
大类 | 4 区 医学
小类 | 4 区 心脏和心血管系统
JCR分区:
出版当年[2016]版:
Q4 CARDIAC & CARDIOVASCULAR SYSTEMS
最新[2023]版:
Q4 CARDIAC & CARDIOVASCULAR SYSTEMS

影响因子: 最新[2023版] 最新五年平均 出版当年[2016版] 出版当年五年平均 出版前一年[2015版] 出版后一年[2017版]

第一作者:
第一作者机构: [1]Department of Cardiology, Beijing Anzhen Hospital, CapitalMedical University, Beijing, China
通讯作者:
通讯机构: [1]Department of Cardiology, Beijing Anzhen Hospital, CapitalMedical University, Beijing, China [*1]Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University No. 2 Beijing Anzhen Road, Chaoyang District, 100029 Beijing, China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:16399 今日访问量:0 总访问量:869 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学宣武医院 技术支持:重庆聚合科技有限公司 地址:北京市西城区长椿街45号宣武医院